Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck’s Capital Idea: Pharma’s Latest Attempt to Get Closer to VCs

Executive Summary

Competition for biotech’s most eligible assets has never been stronger. As such, some pharmas are trying harder than ever to get in on the ground floor.

You may also be interested in...



Merck Adds Flagship To Its Venture Fund Network

Merck contributes to Flagship’s latest fund, both sides promise to share ideas and expertise, but Merck gets no special rights to companies or products in Flagship’s portfolio.

Pharma Plus: Merck’s Global Health Innovation Fund

Realizing that future winners in the health care world will be those companies with broad-based and comprehensive health care offerings, Merck & Co. Inc. tasked a group of executives with identifying and pursuing investment opportunities in what it calls health care adjacencies.

Lilly's Evolving Corporate Venture Model

Of all the big pharmaceutical companies, Eli Lilly & Co. has arguably been the most aggressive and creative in finding outsiders to help develop their drugs. With its latest venture, Lilly hopes to learn lessons from a past failed initiative. The Indianapolis drug firm is set to put up to $150 million to work, backing three traditional venture funds as part of a strategy that outsources development of its own molecules.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053841

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel